| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA631190 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 2. | ALA631191 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 3. | ALA631192 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day. | Human alphaherpesvirus 1 | 2 | ALA1123083 | organism-based format | Scientific Literature | |
| 4. | ALA632400 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 5. | ALA630564 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 6. | ALA630565 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 7. | ALA630566 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 8. | ALA631229 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 9. | ALA631230 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 10. | ALA625672 | A | Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 11. | ALA625673 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 12. | ALA625674 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously. | Human alphaherpesvirus 1 | 2 | ALA1123083 | organism-based format | Scientific Literature | |
| 13. | ALA625675 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 14. | ALA627637 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 15. | ALA627638 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally. | Human alphaherpesvirus 1 | 2 | ALA1123083 | organism-based format | Scientific Literature | |
| 16. | ALA627639 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 17. | ALA627640 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously. | Human alphaherpesvirus 1 | 2 | ALA1123083 | organism-based format | Scientific Literature | |
| 18. | ALA627641 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally. | Human alphaherpesvirus 1 | 2 | ALA1123083 | organism-based format | Scientific Literature | |
| 19. | ALA627642 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature | |
| 20. | ALA877506 | A | Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally. | Human alphaherpesvirus 1 | 1 | ALA1123083 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!